Aevi Genomic Medicine (GNMX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2019 | 06-2019 | 03-2019 | 12-2018 | 09-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -12,526 | -8,484 | -4,839 | -30,775 | -24,149 |
| Depreciation Amortization | 19 | 19 | 16 | 65 | 49 |
| Accounts payable and accrued liabilities | -1,459 | -1,280 | -846 | 639 | 642 |
| Other Working Capital | -325 | -1,058 | -933 | 971 | 2,693 |
| Other Operating Activity | 2,596 | 2,164 | 1,474 | 2,451 | 1,643 |
| Operating Cash Flow | $-11,695 | $-8,639 | $-5,128 | $-26,649 | $-19,122 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $0 | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 2,000 | N/A | N/A | N/A | N/A |
| Common Stock Issued | N/A | N/A | N/A | 4,996 | 4,995 |
| Financing Cash Flow | $2,000 | $N/A | $N/A | $4,996 | $4,995 |
| Beginning Cash Position | 12,076 | 12,076 | 12,076 | 33,729 | 33,729 |
| End Cash Position | 2,381 | 3,437 | 6,948 | 12,076 | 19,602 |
| Net Cash Flow | $-9,695 | $-8,639 | $-5,128 | $-21,653 | $-14,127 |
| Free Cash Flow | |||||
| Operating Cash Flow | -11,695 | -8,639 | -5,128 | -26,649 | -19,122 |
| Free Cash Flow | -11,695 | -8,639 | -5,128 | -26,649 | -19,122 |